SP-420抑制剂

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: SP-420抑制剂
• 中文别名: (4S)-4,5-二氢-2-[2-羟基-4-[2-(2-甲氧基乙氧基)乙氧基]苯基]-4-甲基-4-噻唑羧酸
• 英文名称: 2-[2-hydroxy-4-[2-(2-methoxyethoxy)ethoxy]phenyl]-4-methyl-5H-1,3-thiazole-4-carboxylic acid
• 化学式: C₁₆H₂₁NO₆S
• 分子量: 355.4
• InChiKey: YASYAEVZKXPYIZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  123
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS
  申请人：Malecha James

  公开号：US20110275636A1

  公开（公告）日：2011-11-10

  Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.

  本文披露了新的去氮去除铁硫胺聚醚（DADFT-PE）类似物化合物，以及包含它们的药物组合物，以及它们作为金属螯合剂用于治疗疾病的应用。还提供了在人类或动物主体中螯合铁和其他金属的方法，用于治疗金属过载和中毒。
• DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS
  申请人：Abfero Pharmaceuticals, Inc.

  公开号：EP3493801A1

  公开（公告）日：2019-06-12
• US9045440B2
  申请人：——

  公开号：US9045440B2

  公开（公告）日：2015-06-02
• [EN] DESAZADESFERROTHIOCIN AND DESAZADESFERROTHIOCIN POLYETHER ANALOGUES AS METAL CHELATION AGENTS<br/>[FR] ANALOGUES DE DÉSAZADESFERROTHIOCINE ET DE POLYÉTHER DE DÉSAZADESFERROTHIOCINE UTILISÉS EN TANT QUE CHÉLATEURS MÉTALLIQUES
  申请人：FERROKIN BIOSCIENCES INC

  公开号：WO2011140232A2

  公开（公告）日：2011-11-10

  Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT- PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of metal overload and toxicity.
• [EN] DOSING REGIMENS FOR TREATING METAL-MEDIATED CONDITIONS<br/>[FR] RÉGIMES POSOLOGIQUES POUR LE TRAITEMENT D'ÉTATS À MÉDIATION PAR UN MÉTAL
  申请人：ABFERO PHARMACEUTICALS INC

  公开号：WO2018027132A1

  公开（公告）日：2018-02-08

  The present disclosure provides safe and effective dosing regimens of metal chelators as treatment for metal overload disorders and, in particular, iron overload and associated conditions.